Search | IOVS | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Pharmacological characterization and safety of the Nintedanib IVT XR ocular implant

Florian Andreas Colbatzky Andreas Colbatzky; Paul Ashton; Holger Fuchs; Hong Guo; Jianbing Chen; Remko Bakker

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6111.

ARVO Annual Meeting Abstract June 2022

Trends for Proliferative Diabetic Retinopathy Vitrectomy Treatments in the IRIS ® Registry (Intelligent Research in Sight)

Christine L. Xu; Arthur Brant; Suzann Pershing; Kapil Mishra; Ashton Tristan Perlroth; Henry Bair; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2195 – F0258.

ARVO Annual Meeting Abstract June 2022

Trends of PRP and Anti-VEGF for NPDR in the IRIS ® Registry (Intelligent Research in Sight), 2016-2018

Henry Bair; Arthur Brant; Suzann Pershing; Kapil Mishra; Ashton Tristan Perlroth; Christine Xu; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2196 – F0259.

ARVO Annual Meeting Abstract June 2022

Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS ® Registry (Intelligent Research in Sight)

Kapil Mishra; Arthur Brant; Suzann Pershing; Ashton Tristan Perlroth; Henry Bair; Christine Xu; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2541 – A0110.

ARVO Annual Meeting Abstract June 2022

Progression and Regression of Diabetic Retinopathy in the IRIS ® Registry (Intelligent Research in Sight)

Arthur Brant; Kapil Mishra; Ashton Tristan Perlroth; Henry Bair; Christine Xu; Suzann Pershing; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2175 – F0238.

ARVO Annual Meeting Abstract June 2022

Visual Outcomes post-PPV for Tractional Retinal Detachment or Vitreous Hemorrhage in the Intelligent Research in Sight (IRIS) Registry

Ashton Tristan Perlroth; Arthur Brant; Suzann Pershing; Kapil Mishra; Henry Bair; Christine Xu; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):584 – A0149.

ARVO Annual Meeting Abstract June 2021

The Impact of the COVID-19 Pandemic on Intravitreal Bevacizumab Use

Ashton Perlroth; Kapil Mishra; Diana V Do

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):300.

Genetics May 2013

Screening of RB1 Alterations in Brazilian Patients With Retinoblastoma and Relatives With Retinoma: Phenotypic and Genotypic Associations

PDF

Raquel H. Barbosa; Fernanda C. C. Aguiar; Morgana F. L. Silva; Regis A. Costa; Fernando R. Vargas; Evandro Lucena; Mírian Carvalho de Souza; Liz Maria de Almeida; Camila Bittar; Patrícia Ashton Prolla; Cibele R. Bonvicino; Héctor N. Seuánez
TAGS: genotype, introns, phenotype, retinoblastoma, screening, recurrence, neoplasms, survival rate
Invest. Ophthalmol. Vis. Sci.. 2013; 54(5):3184-3194. https://doi.org/10.1167/iovs.13-11686

Includes: Supplemental Content

Retina August 2010

Intravitreous Delivery of the Corticosteroid Fluocinolone Acetonide Attenuates Retinal Degeneration in S334ter-4 Rats

PDF

Inna V. Glybina; Alexander Kennedy; Paul Ashton; Gary W. Abrams; Raymond Iezzi
TAGS: adrenal corticosteroids, electroretinography, eye, fluocinolone acetonide, glucocorticoids, microglia, mineralocorticoids, rats, retinal degeneration, retina
Invest. Ophthalmol. Vis. Sci.. 2010; 51(8):4243-4252. https://doi.org/10.1167/iovs.09-4492

Retina October 2009

Photoreceptor Neuroprotection in RCS Rats via Low-Dose Intravitreal Sustained-Delivery of Fluocinolone Acetonide

PDF

Inna V. Glybina; Alexander Kennedy; Paul Ashton; Gary W. Abrams; Raymond Iezzi
TAGS: electroretinography, eye, fluocinolone acetonide, microglia, neuroprotection, photoreceptors, rats, retina, histology, significance
Invest. Ophthalmol. Vis. Sci.. 2009; 50(10):4847-4857. https://doi.org/10.1167/iovs.08-2831

ARVO Annual Meeting Abstract April 2009

Silicon Based Sustained Release Systems

P. Ashton; H. Guo; J. Chen; L. Canham

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):5989.

ARVO Annual Meeting Abstract April 2009

Sustained Release Celecoxib From Bioerodible Intraocular Devices

J. Chen; H. Guo; G. Cynkowska; T. Cynkowski; P. Ashton

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4993.

ARVO Annual Meeting Abstract May 2008

Fluocinolone Acetonide-Mediated Neuroprotection in S334-ter-4 Rat Retinal Degeneration

R. Iezzi; I. V. Glybina; A. Kennedy; P. Ashton; G. W. Abrams

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):2036.

ARVO Annual Meeting Abstract May 2006

Neuroprotective Properties of Fluocinolone Acetonide Chronically Delivered into the Vitreous of Albino RCS Rats

I.V. Glybina; R. Iezzi; P. Ashton; G. Abrams

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1028.

ARVO Annual Meeting Abstract May 2006

Safety and Drug Release Profile of Injectable Intravitreal Sustained–Release Fluocinolone Acetonide Device

R.F. See; J.J. Peairs; S. Srivastava; P. Mruthyunjaya; S.S. Stinnett; H. Guo; M. Nazzaro; P. Ashton; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5119.

ARVO Annual Meeting Abstract May 2005

Pharmocological Effects of Intravitreal Fluocinolone Acetonide in RCS Rats With Chronic Subretinal Prothesis Implants

K.R. Wong; I.V. Glybina; R. Buddi; S. Rabbani; J.P. McAllister; P. Ashton; G.W. Abrams; R. Iezzi

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1510.

ARVO Annual Meeting Abstract May 2003

Possible Role of Endotoxin in a Complication After Intravitreal Triamcinolone Acetonide Injection

P. Ashton; P.A. Pearson; L.S. Halperin; S. Talbott; J. Martin

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1858.

ARVO Annual Meeting Abstract May 2003

Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients with Severe Uveitis

J.P. Denny; A. Carlson; R. McCallum; P. Ashton; B. Branchaud; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2410.

ARVO Annual Meeting Abstract May 2003

Fluocinolone Acetonide Formulated with Sodium Hyaluronate as a Sustained Release Drug Delivery Pellet in the Treatment of Experimental Proliferative Vitreoretinopathy

D. Khalatbari; P. Mruthyunjaya; P. Yang; S. Stinnett; J. Chen; P. Ashton; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):3009.

ARVO Annual Meeting Abstract December 2002

Fluocinolone Acetonide Sustained Drug Delivery System in the Treatment of Experimental Proliferative Vitreoretinopathy

P Mruthyunjaya; W Tseng; S Stinnett; P Ashton; GJ Jaffe

Invest. Ophthalmol. Vis. Sci.. 2002; 43(13):3003.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Pharmacological characterization and safety of the Nintedanib IVT XR ocular implant

Trends for Proliferative Diabetic Retinopathy Vitrectomy Treatments in the IRIS ® Registry (Intelligent Research in Sight)

Trends of PRP and Anti-VEGF for NPDR in the IRIS ® Registry (Intelligent Research in Sight), 2016-2018

Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS ® Registry (Intelligent Research in Sight)

Progression and Regression of Diabetic Retinopathy in the IRIS ® Registry (Intelligent Research in Sight)

Visual Outcomes post-PPV for Tractional Retinal Detachment or Vitreous Hemorrhage in the Intelligent Research in Sight (IRIS) Registry

The Impact of the COVID-19 Pandemic on Intravitreal Bevacizumab Use

Screening of RB1 Alterations in Brazilian Patients With Retinoblastoma and Relatives With Retinoma: Phenotypic and Genotypic Associations

Intravitreous Delivery of the Corticosteroid Fluocinolone Acetonide Attenuates Retinal Degeneration in S334ter-4 Rats

Photoreceptor Neuroprotection in RCS Rats via Low-Dose Intravitreal Sustained-Delivery of Fluocinolone Acetonide

Silicon Based Sustained Release Systems

Sustained Release Celecoxib From Bioerodible Intraocular Devices

Fluocinolone Acetonide-Mediated Neuroprotection in S334-ter-4 Rat Retinal Degeneration

Neuroprotective Properties of Fluocinolone Acetonide Chronically Delivered into the Vitreous of Albino RCS Rats

Safety and Drug Release Profile of Injectable Intravitreal Sustained–Release Fluocinolone Acetonide Device

Pharmocological Effects of Intravitreal Fluocinolone Acetonide in RCS Rats With Chronic Subretinal Prothesis Implants

Possible Role of Endotoxin in a Complication After Intravitreal Triamcinolone Acetonide Injection

Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients with Severe Uveitis

Fluocinolone Acetonide Formulated with Sodium Hyaluronate as a Sustained Release Drug Delivery Pellet in the Treatment of Experimental Proliferative Vitreoretinopathy

Fluocinolone Acetonide Sustained Drug Delivery System in the Treatment of Experimental Proliferative Vitreoretinopathy

To View More...

You must be signed into an individual account to use this feature.